Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.

Inamoto, Yoshihiro; Valdés-Sanz, Nuria; Ogawa, Yoko; Alves, Monica; Berchicci, Luigi; Galvin, John; Greinix, Hildegard; Hale, Gregory A; Horn, Biljana; Kelly, Debra; Liu, Hien; Rowley, Scott; Schoemans, Helene; Shah, Ami; Lupo Stanghellini, Maria Teresa; Agrawal, Vaibhav; Ahmed, Ibrahim; Ali, Asim; Bhatt, Neel; Byrne, Michael; ... (2019). Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone marrow transplantation, 54(5), pp. 662-673. Nature Publishing Group 10.1038/s41409-018-0340-0

[img] Text
s41409-018-0340-0.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (794kB) | Request a copy

Ocular graft-versus-host disease (GVHD) occurs in more than half of patients who develop chronic GVHD after allogeneic hematopoietic cell transplantation (HCT), causing prolonged morbidity, which affects activities of daily living and quality of life. Here we provide an expert review of ocular GVHD in a collaboration between transplant physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Recent updates in ocular GVHD, regarding pathophysiology, preclinical models, risk factors, prevention, screening, diagnosis, response criteria, evaluation measures, and treatment are discussed in this review. Ocular GVHD has at least three biological processes: lacrimal gland dysfunction, meibomian gland dysfunction, and corneoconjunctival inflammation. Preclinical models have found several novel pathogenic mechanisms, including renin angiotensin system and endoplasmic reticulum stress signaling that can be targeted by therapeutic agents. Many studies have identified reliable tests for establishing diagnosis and response assessment of ocular GVHD. Efficacy of systemic and topical treatment for ocular GVHD is summarized. It is important for all health professionals taking care of HCT recipients to have adequate knowledge of ocular GVHD for optimal care.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory

UniBE Contributor:

Rovó, Alicia

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0268-3369

Publisher:

Nature Publishing Group

Language:

English

Submitter:

Pierrette Durand Lüthi

Date Deposited:

08 Jan 2019 12:33

Last Modified:

03 May 2019 01:31

Publisher DOI:

10.1038/s41409-018-0340-0

PubMed ID:

30531954

BORIS DOI:

10.7892/boris.123259

URI:

https://boris.unibe.ch/id/eprint/123259

Actions (login required)

Edit item Edit item
Provide Feedback